Skip to content
TradingPilot
Performance
Theme
Sign in

News & calendar

news: as of 2026-10-06
What the marks mean

Importance is a model-assigned 1–5 on published stories, not a market forecast.

Impact on a scheduled row is a company-prominence tier (High/Medium from graph centrality and size; Low only on curated minor events), not a magnitude forecast.

An earnings date marked confirmed is company-confirmed by Yahoo Finance; estimated is not yet announced. Unmarked rows carry no recorded provenance.

Economic releases are macro and carry no industry, so they stay in every view. A release with no value has not printed yet and says so rather than showing a zero.

Upcoming events across the tracked universe; past events are archived, with outcomes added where available — curated and cited, never fabricated. A past row without one reads “outcome pending”.

A lock-up or index change row adds one line of arithmetic — shares becoming sellable, or shares index funds must buy, as a share of float — read off the prospectus or the index methodology, with both numbers cited in the row. It states the mechanics, not a price move. A lock-up date derived as IPO + 180 days stays estimated until the company states it.

Ahead

scheduled · today and tomorrow · calendar refreshed 2026-10-12

Mon · 12 Oct · today

Tue · 13 Oct

Behind

published · newest first

Mon · 17 Aug

regulation

18:21
Business Wire

LYNKUET (elinzanetant) Receives Expanded Market Authorization in Canada for Treatment of Moderate to Severe Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy (AET) Related to Breast Cancer

Bayer announced that Health Canada issued a Notice of Compliance expanding the indication for LYNKUET (elinzanetant) to the treatment of moderate to severe vasomotor symptoms caused by adjuvant endocrine therapy related to breast cancer, making it the first approved treatment option in Canada for that patient population. The expansion builds on Health Canada's July 2025 authorization of LYNKUET for moderate to severe VMS associated with menopause and was supported by Bayer's OASIS-4 study. LYNKUET is a once-daily oral, non-hormonal dual neurokinin-targeted therapy antagonizing both NK-1 and NK-3 receptors.

Markets open original ↗

personnel

17:27
Spectrum News 13

United Launch Alliance names Mark Peller president and CEO

United Launch Alliance named Mark Peller president and chief executive officer, with the new role starting immediately. Peller was previously chief operating officer overseeing Atlas and Vulcan rocket operations and joined ULA at its formation in 2006. He replaces interim CEO John Elbon, who stepped in after Tory Bruno left eight months earlier to lead Blue Origin's National Security Group. ULA is a joint venture whose board chair is Robert Lightfoot, president of Lockheed Martin Space, with Boeing represented by Kay Sears, vice president and general manager of Space, Intelligence & Weapon Systems.

Markets open original ↗

earnings

12:21
GlobeNewswire

Novo Nordisk A/S - share repurchase programme

Novo Nordisk filed its weekly buyback disclosure. The overall programme is for up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026, with the current tranche of up to DKK 11,200,000,010.45 running from 6 May 2026 to 1 February 2027. In the 10-14 August 2026 window the company repurchased 1,000,000 B shares, bringing the cumulative total under the tranche to 14,125,000 B shares for DKK 4,281,660,830. Following the transactions Novo Nordisk holds 42,924,876 B shares of DKK 0.10 as treasury shares, corresponding to 1.0% of the share capital.

Markets open original ↗

partnership

12:10
Yahoo Finance

RTX's Raytheon awarded $22.9 billion seven-year Tomahawk production contract

Raytheon, an RTX business, was awarded a $22.9 billion, seven-year contract by the U.S. Department of War covering an annual production ramp to more than 1,000 Tomahawk missiles and associated support. RTX said it delivered three times more Tomahawks in the first half of 2026 than in the same period of 2025. Raytheon President Phil Jasper said "Tomahawk is the Navy's most important strike weapon, able to target hostile forces hundreds of miles away without ever risking the lives of our sailors."

Markets open original ↗

personnel

11:30
L3Harris Technologies

L3Harris removes CEO Chris Kubasik over conduct, names Sam Mehta president and CEO

L3Harris Technologies appointed Sam Mehta as President and Chief Executive Officer and a member of the Board, effective immediately, after the board identified certain conduct by Chris Kubasik that was not consistent with the values of the company as outlined in its Code of Conduct — conduct L3Harris said was unrelated to financial reporting, controls, customer relationships or operational performance. Lead Independent Director Lewis Hay III was named Independent Chairman of the Board. Mehta most recently led the Space & Mission Systems and Communications & Spectrum Dominance segments and previously held leadership positions at Collins Aerospace and Sikorsky Aircraft. L3Harris reaffirmed its 2026 consolidated revenue, organic growth, segment operating margin, GAAP earnings per share and free cash flow.

Markets open original ↗

The wire

everything that arrived · 7 days